Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction

Metabolism: Clinical and Experimental

Volumn 60, Issue 2, 2011, Pages 306-311

  Mai, Knut ^a   Schwarz, Franziska ^a   Bobbert, Thomas ^a   Andres, Janin ^a   Assmann, Anke ^a   Pfeiffer, Andreas F H ^a,b   Spranger, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; LIPID;

ABDOMINAL OBESITY; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); ENERGY BALANCE; FEMALE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MALE; METABOLISM; OBESITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ABDOMINAL FAT; ADIPOSITY; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE; HUMANS; INSULIN; LIPID METABOLISM; MALE; MIDDLE AGED; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 78751656242     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.02.016     Document Type: Article

References (26)

1. Inagaki T., Dutchak P., and Zhao G. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21 Cell Metab 5 2007 415 425
2. Kharitonenkov A., Shiyanova T.L., and Koester A. FGF-21 as a novel metabolic regulator J Clin. Invest 115 2005 1627 1635
3. Galman C., Lundasen T., and Kharitonenkov A. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man Cell Metab 8 2008 169 174
4. Kharitonenkov A., Wroblewski V.J., and Koester A. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 Endocrinology 148 2007 774 781
5. Zhang X., Yeung D.C., and Karpisek M. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans Diabetes 57 2008 1246 1253
6. Chen W.W., Li L., and Yang G.Y. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus Exp. Clin. Endocrinol. Diabetes 116 2008 65 68
7. Mraz M., Bartlova M., and Lacinova Z. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity Clin. Endocrinol. (Oxf) 71 2009 369 375
8. Mai K., Andres J., and Biedasek K. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21 Diabetes 58 2009 1532 1538
9. Potthoff M.J., Inagaki T., and Satapati S. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response Proc. Natl. Acad. Sci. U.S.A 106 2009 10853 10858
10. Rochlitz H., Akpulat S., and Bobbert T. [Significance of biomarkers for metabolic syndrome during weight reduction] Dtsch. Med. Wochenschr. 130 2005 1061 1066
11. Bobbert T., Rochlitz H., and Wegewitz U. Changes of adiponectin oligomer composition by moderate weight reduction Diabetes 54 2005 2712 2719
12. Spranger J., Kroke A., and Mohlig M. Adiponectin and protection against type 2 diabetes mellitus Lancet 361 2003 226 228
13. Spranger J., Kroke A., and Mohlig M. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study Diabetes 52 2003 812 817
14. Mai K., Andres J., and Bobbert T. Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue Clin. Endocrinol (Oxf) 67 2007 419 425
15. Mai K., Bobbert T., and Reinecke F. Intravenous lipid and heparin infusion-induced elevation in free fatty acids and triglycerides modifies circulating androgen levels in women: a randomized, controlled trial J Clin. Endocrinol Metab 93 2008 3900 3906
16. Matthews D.R., Hosker J.P., and Rudenski A.S. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
17. Pfluger P.T., Kampe J., and Castaneda T.R. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36 J Clin. Endocrinol Metab 92 2007 583 588
18. Arner P., Pettersson A., and Mitchell P.J. FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity FEBS Letters 582 2008 1725 1730
19. Li H., Bao Y., and Xu A. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects J. Clin. Endocrinol. Metab 94 2009 2151 2156
20. Chavez A.O., Molina-Carrion M., and bdul-Ghani M.A. Circulating fibroblast growth factor-21 (FGF-21) is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance Diabetes Care 2009
21. Li L., Yang G., and Ning H. Plasma FGF-21 levels in type 2 diabetic patients with ketosis Diabetes Res.Clin.Pract. 82 2008 209 213
22. Valsamakis G., McTernan P.G., and Chetty R. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines Metabolism 53 2004 430 434
23. Sato F., Tamura Y., and Watada H. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects J. Clin. Endocrinol. Metab 92 2007 3326 3329
24. Christodoulides C., Dyson P., and Sprecher D. Circulating FGF21 is induced by PPAR agonists but not ketosis in man J. Clin. Endocrinol. Metab 2009
25. Kharitonenkov A., and Shanafelt A.B. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases BioDrugs 22 2008 37 44
26. Badman M.K., Pissios P., and Kennedy A.R. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states Cell Metab 5 2007 426 437